N-acylic aminoacid derivatives, method for the production thereof, pharmacological composition and the use in the form anti-allergic, anti-inflammatory and hypolipidemic agents
The present invention relates to N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereof wherein n is 2 or 3; and R 1 represents or pharmaceutically acceptable salts thereof, to novel processes for preparing the same, to use thereof as anti-allergic, anti-anaphylactic, anti-inflammatory and hypolipidemic agents as well as to a pharmaceutical composition comprising the indicated compounds in an efficient amount and to a method for treating allergic and inflammatory diseases and lipid metabolism disorders: bronchial asthma, allergic rhinitis, pollinoses, seasonal and year-round rhinitis, allergic pneumonitis, atopic dermatitis, psoriasis, urticaria, allergic (including anaphylactic) reactions to insect stings and medicaments, cold allergy, allergic conjunctivitis, atherosclerosis, obesity, ischemic heart and cerebral disease, myocardial infarction and stroke.
1. N-acyl derivatives of amino acids of general formula I
wherein n is 2 or 3; and
R 1 represents
or a pharmaceutically acceptable salt thereof,
with proviso that the compound of general formula I is not succinyl-L-tryptophane, succinyl-D-tryptophane and succinyl-D,L-tryptophane and a dipotassium salt thereof, N α -succinyl-L-tryptophane methyl ester, N α -glutaryl-L-histidine methyl ester, N α -glutaryl-L-tryptophane, N α -glutaryl-L-tryptophane methyl ester, N α -succinyl-L-histidine, N α -glutaryl-D-tryptophane methyl ester, N α -glutaryl-L-histidine, or N α -glutaryl-L-histidine ethyl ester.
2. The compound according to claim 1 , wherein the pharmaceutically acceptable salt is a mono- or disodium salt.
3. A pharmaceutical composition comprising an N-acyl derivative of an amino acid of formula I
wherein n is 2 or 3; and
R 1 represents
or a pharmaceutically acceptable salt thereof
with proviso that the N-acyl derivative of formula I is not succinyl-L-tryptophane, succinyl-D-tryptophane and succinyl-D,L-tryptophane and a dipotassium salt thereof, N α -succinyl-L-tryptophane methyl ester, N α -glutaryl-L-histidine methyl ester, N α -glutaryl-L-tryptophane methyl ester, N α -succinyl-L-histidine, N α -glutaryl-D-triptophane methyl ester, N α -glutaryl-L-triptophane, N α -glutaryl-L-histidine, or N α -glutaryl-L-histidine ethyl ester,
and a pharmaceutically acceptable additive, wherein the N-acyl derivative or pharmaceutically acceptable salt thereof is present in the composition in an amount effective to possess anti-allergic, anti-anaphylactic, or anti-inflammatory activity.
4. A method for lowering antigen-dependent histamine secretion, basophil degranulation or controlling the level of eosinophils, neutrophils or lymphocytes in a mammal, the method comprising administering to the mammal a compound of claim 1 or a pharmaceutically acceptable salt thereof.
5. A medicament comprising an N-acyl derivative of an amino acid of formula I
wherein n is 2 or 3; and
R 1 represents
or a pharmaceutically acceptable salt thereof
with proviso that the N-acyl derivative of formula I is not succinyl-L-tryptophane, succinyl-D-tryptophane and succinyl-D,L-tryptophane and a dipotassium salt thereof, N α -succinyl-L-tryptophane methyl ester, N α -glutaryl-L-histidine methyl ester, N α -glutaryl-L-tryptophane methyl ester, N α -succinyl-L-histidine, N α -glutaryl-D-triptophane methyl ester, N α -glutaryl-L-triptophane, N α -glutaryl-L-histidine, or N α -glutaryl-L-histidine ethyl ester,
wherein the N-acyl derivative or pharmaceutically acceptable salt thereof is present in the medicament in an amount effective to possess anti-allergic, anti-anaphylactic, anti-inflammatory activity.
6. A method for treating an indication selected from the group consisting of bronchial asthma, psoriasis, atherosclerosis, obesity, ischemic heart disease, ischemic cerebral disease, myocardial infarction, and stroke, comprising administration to a mammal in need of such treatment of an effective amount of the compound of claim 1
or a pharmaceutically acceptable salt thereof.
7. A method for treating an indication selected from the group consisting of allergic rhinitis, pollinoses, seasonal rhinitis, year-round rhinitis, allergic pneumonitis, atopic dermatitis, urticaria, allergic (including anaphylactic) reactions to insect stings and medicaments, cold allergy, and allergic conjunctivitis, comprising administration to a mammal in need of such treatment of an effective amount of the compound of general formula I of claim 1
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising an N-acyl derivative of an amino acid of formula I
wherein n is 2 or 3; and
R 1 represents
or a pharmaceutically acceptable salt thereof
with proviso that the N-acyl derivative of Formula I is not succinyl-L-tryptophane, succinyl-D-tryptophane and succinyl-D,L-tryptophane and a dipotassium salt thereof, N α -succinyl-L-tryptophane methyl ester, N α -glutaryl-L-histidine methyl ester, N α -glutaryl-L-tryptophane methyl ester, N α -succinyl-L-histidine, N α -glutaryl-D-triptophane methyl ester, N α -glutaryl-L-triptophane, N α -glutaryl-L-histidine, or N α -glutaryl-L-histidine methyl ester
and a pharmaceutically acceptable additive wherein the N-acyl derivative or pharmaceutically acceptable salt thereof is present in the composition in an amount effective for lowering antigen-dependent histamine secretion, basophil degranulation and controlling the level of eosinophils, neutrophils and lymphocytes.
9. The pharmaceutical composition of claim 3 for treating bronchial asthma or psoriasis.
10. A pharmaceutical composition comprising an effective amount of the compound of general formula I
wherein n is 2 or 3; and
R 1 represents
or a pharmaceutically acceptable salt thereof,
with proviso that the compound of general formula I is not succinyl-L-tryptophane, succinyl-D-tryptophane and succinyl-D, L-tryptophane and a dipotassium salt thereof, N α -succinyl-L-tryptophane methyl ester, N α -glutaryl-L-histidine methyl ester, N α -glutaryl-L-tryptophane methyl ester, N α -succinyl-L-histidine, N α -glutaryl-D-triptophane methyl ester, N α -glutaryl-L-triptophane, N α -glutaryl-L-histidine, or N α -glutaryl-L-histidine ethyl ester,
and a pharmaceutically acceptable additive, wherein the compound is present in the composition in an amount effective for treating an indication selected from the group consisting of allergic rhinitis, pollinoses, seasonal rhinitis, -year-round rhinitis, allergic pneumonitis, atopic dermatitis, urticaria, allergic (including anaphylactic) reactions to insect stings, allergic reactions to medicaments, cold allergy, and allergic conjunctivitis.
11. A pharmaceutical composition comprising an N-acyl derivative of an amino acid of general formula I
wherein n is 2 or 3; and
R 1 represents
or a pharmaceutically acceptable salt thereof,
with proviso that the N-acyl derivative is not succinyl-L-tryptophane, succinyl-D-tryptophane and succinyl-D,L-tryptophane and a dipotassium salt thereof, N α -succinyl-L-tryptophane methyl ester, N α -glutaryl-L-histidine methyl ester, N α -glutaryl-L-tryptophane methyl ester, N α -succinyl-L-histidine, N α -glutaryl-D-triptophane methyl ester, N α -glutaryl-L-triptophane, N α -glutaryl-L-histidine ethyl ester, and pharmaceutically acceptable additives, wherein the N-acyl derivative or pharmaceutically acceptable salt thereof is present in the composition in an amount effective to possess hypolipidemic activity.
12. The pharmaceutical composition according to claim 11 for wherein the N-acyl derivative or pharmaceutically acceptable salt thereof is present in the composition in an amount effective for treating an indication selected from the group consisting of atherosclerosis, obesity, ischemic heart disease, ischemic cerebral disease, myocardial infarction, and stroke.
13. A medicament comprising an N-acyl derivative of an amino acid of general formula I
wherein n is 2 or 3; and
R 1 represents
or a pharmaceutically acceptable salt thereof,
with proviso that the compound of general formula I is not succinyl-L-tryptophane, succinyl-D-tryptophane and succinyl-D,L-tryptophane and a dipotassium salt thereof, N α -succinyl-L-tryptophane methyl ester, N α -glutaryl-L-histidine methyl ester, N α -glutaryl-L-tryptophane methyl ester, N α -succinyl-L-histidine, N α -glutaryl-D-triptophane methyl ester, N α -glutaryl-L-triptophane, N α -glutaryl-L-histidine ethyl ester, wherein the N-acyl derivative or pharmaceutically acceptable salt thereof is present in the medicament in an amount effective to possess hypolipidemic activity.
14. A compound selected from the group consisting of N α -glutaryl-L-histidine monosodium salt and N α -glutaryl-L-histidine disodium salt.
15. The compound according to claim 14 for increasing high density lipoproteins.
16. A pharmaceutical composition comprising a compound selected from the group consisting of N α -glutaryl-L-histidine, N α -glutaryl-L-histidine monosodium salt, N α -glutaryl-L-histidine disodium salt, N α -succinyl-L-tryptophane monosodium salt, N α -glutaryl-L-tryptophane monosodium salt and N α -succinyl-L-histidine monosodium salt and a pharmaceutically acceptable additive, wherein the compound is present in an amount effective to increase high density lipoproteins.
17. A medicament for increasing high density lipoproteins comprising a compound selected from the group consisting of N α -glutaryl-L-histidine, N α -glutaryl-L-histidine monosodium salt, N α -glutaryl-L-histidine disodium salt, N α -succinyl-L-tryptophane monosodium salt, N α -glutaryl-L-tryptophane monosodium salt and N α -succinyl-L-histidine monosodium salt, wherein compound is present in an amount effective to increase high density lipoproteins.